X
Pharma Advancement
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    development of new antibiotics

    EMA guidance supports development of new antibiotics

    Thermo Fisher Scientific Announces Collaboration with Northeastern University to Advance Biopharmaceutical Characterization and Monitoring Workflows

    Commercial Success In New Biopharmaceutical Innovation Era

    Proteros and AstraZeneca Boost Collaboration Agreement

    Conver to wp

    AbbVie and Cugene Join Forces Concerning Autoimmune Disorders and Cancer

    Drug Imagent For Therapeutic Platform

    Japan Pharma Lobby Says-Price Scheme Is Causing Drug Lag

    Charles River and Valence Discovery Announce Strategic Partnership to Provide Clients with AI-Enabled Drug Design Capabilities

    Charles River and Valo Launch Logica, an Integrated AI-Powered Drug Discovery Solution to Rapidly Deliver Optimized Preclinical Assets

    AstraZeneca announces phase IV ASCENT trial of Tudorza Pressair in patients with COPD meets primary efficacy endpoint

    AstraZeneca announces plans for new strategic R&D centre and Alexion headquarters in Cambridge, Massachusetts

    Lynparza approved in the EU for BRCA-mutated metastatic pancreatic cancer

    Major Success Factors For Clinical Development Organizations

    ArisGlobal Expands LifeSphere Clinical Portfolio with Landmark Customer Wins in APAC & Middle East

    ArisGlobal Expands LifeSphere Clinical Portfolio with Landmark Customer Wins in APAC & Middle East

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    development of new antibiotics

    EMA guidance supports development of new antibiotics

    Thermo Fisher Scientific Announces Collaboration with Northeastern University to Advance Biopharmaceutical Characterization and Monitoring Workflows

    Commercial Success In New Biopharmaceutical Innovation Era

    Proteros and AstraZeneca Boost Collaboration Agreement

    Conver to wp

    AbbVie and Cugene Join Forces Concerning Autoimmune Disorders and Cancer

    Drug Imagent For Therapeutic Platform

    Japan Pharma Lobby Says-Price Scheme Is Causing Drug Lag

    Charles River and Valence Discovery Announce Strategic Partnership to Provide Clients with AI-Enabled Drug Design Capabilities

    Charles River and Valo Launch Logica, an Integrated AI-Powered Drug Discovery Solution to Rapidly Deliver Optimized Preclinical Assets

    AstraZeneca announces phase IV ASCENT trial of Tudorza Pressair in patients with COPD meets primary efficacy endpoint

    AstraZeneca announces plans for new strategic R&D centre and Alexion headquarters in Cambridge, Massachusetts

    Lynparza approved in the EU for BRCA-mutated metastatic pancreatic cancer

    Major Success Factors For Clinical Development Organizations

    ArisGlobal Expands LifeSphere Clinical Portfolio with Landmark Customer Wins in APAC & Middle East

    ArisGlobal Expands LifeSphere Clinical Portfolio with Landmark Customer Wins in APAC & Middle East

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Drug Development Research & Development

Swift Launches Accel-Amplicon Custom NGS Panels, Accelerating Variant Discovery in Challenging Biological Samples

Yuvraj_pawp by Yuvraj_pawp
13th October 2017
in Research & Development

Swift Biosciences, a leading provider of innovative library prep solutions for next-generation sequencing announced the launch of its Accel-Amplicon™ Custom NGS Panels.

These new panels offer a targeted DNA sequencing product that enables clinical researchers to rapidly design highly focused panels to discover, validate and screen disease genes and their variants.

With the quickest workflow, Swift’s Accel-Amplicon Custom NGS Panel is a powerful solution to discover and assess clinically-relevant mutations across targeted genes using multiplexed amplicon sequencing. The panel is platform agnostic and addresses many applications such as fine mapping, variant discovery and screening, post GWAS replication, drug target discovery, clinical trial management and monitoring therapeutic efficacy.


“Our Accel-Amplicon Custom NGS Panels offer a breakthrough for translational researchers to interrogate variants within sample types that were impractical until now,” said Candia Brown, Swift’s Vice President of Global Marketing. “We’ve taken everything we’ve learned from our pre-designed panels and collaborative partnerships to deliver a transformative workflow that helps any laboratory implement targeted sequencing and rapidly uncover new biological insights into complex diseases.”


Key features and benefits of the Accel-Amplicon Custom NGS Panel include:

  • Supports the widest range of input sample types including fresh and fresh-frozen tissue, whole blood, blood spot cards, FFPE, cell-free DNA, circulating tumor DNA, buccal swab, whole genome amplified DNA and purified DNA.
  • Requires the least amount of sample input with only 10 nanograms
  • Enables the fastest library prep workflow in under two hours
  • Provides the only single-tube NGS assay with complete and comprehensive genomic coverage
  • Includes fully optimized and wet-lab validated NGS assays in every design.
  • Supported on either Ion Torrent™ or Illumina® sequencing platforms

To complete this breakthrough workflow, Swift partnered with Genialis, a software solution company, to integrate alignment, trimming, QC and variant calling into one simple pipeline. The Genialis’ cloud application also automates an algorithm optimized for accurate variant detection, including low frequency variants in heterogeneous samples, such as cancer. It is fast and easy to use, as it offers data visualization and annotated variants using direct links to publicly available databases such as COSMIC and NCBI.

“Targeted NGS sequencing is transforming translational research and genomic medicine by allowing researchers to rapidly and confidently screen important variants,” said Rafael Rosengarten, Genialis’ President and Chief Product Officer. “However, data analysis and interpretation is a long-standing bottleneck that has significantly constrained the speed and scale of these studies. This alliance with Swift Biosciences will enable us to deliver our innovative algorithms and interface to transform how researchers call, visualize and annotate variants. This will yield faster discoveries and support broader collaboration between laboratories.”

The Accel-Amplicon Custom NGS Panel is now commercially available. At ASHG 2017, Swift and Genialis will debut the complete targeted sequencing workflow at a Swift educational workshop on October 19. The event, entitled “Harnessing the Power of Next-Generation Sequencing for Precision Medicine” will be held at the Hilton Orlando Hotel, Lake George Ballroom.


About Swift Biosciences

Swift Biosciences is the NGS Library Prep company. Based in Ann Arbor, Michigan, the company develops novel library preparation solutions for emerging applications based on next-generation sequencing, including whole genome sequencing, targeted DNA sequencing, and epigenetic analysis. Swift Biosciences’ products are designed to help customers analyze challenging biological samples faster, easier, and with greater sensitivity and accuracy, while being compatible with leading instrumentation. Swift Biosciences is the first company to offer library preparation solutions on all three major sequencing platforms, including Pacific Biosciences®, Illumina® and Ion Torrent™.

 

The company opened its doors in February 2010, and its product development enables new applications in multiple industries, including agrigenomics, pharmaceutical, academic, biotechnology, and oncology research fields.

Previous Post

Liquid Biopsy Tumor Heterogeneity Test Predicts Resistance to Targeted Therapy In Metastatic Prostate Cancer Patients

Next Post

BrainStorm Enrolls First Patients in Phase 3 Trial of NurOwn® in ALS

Related Posts

Thermo Fisher Scientific Announces Collaboration with Northeastern University to Advance Biopharmaceutical Characterization and Monitoring Workflows
Manufacturing

Commercial Success In New Biopharmaceutical Innovation Era

21st May 2022
Manufacturing

Proteros and AstraZeneca Boost Collaboration Agreement

18th May 2022
SEQENS Makes Multi-Million-Dollar Investment in U.S. R&D Laboratory
Middle East and South Asia

SEQENS Makes Multi-Million-Dollar Investment in U.S. R&D Laboratory

22nd March 2022
Exscientia and Sanofi establish strategic research collaboration to develop AI-driven pipeline of precision-engineered medicines
Press Statements

Exscientia and Sanofi establish strategic research collaboration to develop AI-driven pipeline of precision-engineered medicines

17th January 2022
COVID-19 Impact On Changing Pharma Research And Development
News

COVID-19 Impact On Changing Pharma Research And Development

12th January 2022
immuno-oncology therapies
Drug Development

AbbVie, University of Chicago Extend Research Collaboration to Support Preclinical Oncology Research Through 2025

19th November 2021
Next Post

BrainStorm Enrolls First Patients in Phase 3 Trial of NurOwn® in ALS

Latest News

Dupixent From Sanofi Delivers Another Fantastic Performance
Manufacturing

Sanofi Sets Up Fund To Enable Firms In Low-Income Countries

5th July 2022
GSK commences phase III study of Benlysta and rituximab combination in systemic lupus erythematosus
Manufacturing

Singapore Authorises New Ovarian Cancer Treatment By GSK

5th July 2022
Abbott Is Named Global Industry Leader in Sustainability for the Sixth Consecutive Year on the Dow Jones Sustainability Index (DJSI)
Manufacturing

Abbott India Affirms That The Medicines Are Not Their Own

5th July 2022
Global Biopharmaceutical Bioseparation Market Eyeing $20bn
Manufacturing

Global Biopharmaceutical Bioseparation Market Eyeing $20bn

4th July 2022
FDA Advises Adding Omicron BA.4, 5 To COVID-19 Boosters
Manufacturing

FDA Advises Adding Omicron BA.4, 5 To COVID-19 Boosters

4th July 2022
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack

System

  • Search
  • Sitemap
  • RSS Feed

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In